ImmunityBio Newsroom

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)

TipRanksMay 6 08:35 ET

ImmunityBio Analyst Ratings

BenzingaApr 29 07:50 ET

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Healthcare Services (HCSG) and ImmunityBio (IBRX)

TipRanksApr 29 07:11 ET

ImmunityBio (IBRX) Gets a Hold From Piper Sandler

TipRanksApr 29 07:08 ET

Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)

TipRanksMar 25 06:50 ET

ImmunityBio Analyst Ratings

BenzingaMar 25 06:41 ET

Piper Sandler Reaffirms Their Hold Rating on ImmunityBio (IBRX)

TipRanksNov 14, 2023 07:36 ET

ImmunityBio (IBRX) Gets a Buy From Jefferies

TipRanksMay 15, 2023 09:25 ET

ImmunityBio Downgraded to Neutral at Piper on Bladder Cancer Candidate

Seeking AlphaMay 12, 2023 12:46 ET

Piper Sandler Downgrades ImmunityBio to Neutral, Lowers Price Target to $4

BenzingaMay 12, 2023 05:27 ET

Jefferies Starts ImmunityBio at Buy With $8 Price Target

MT NewswiresAug 3, 2022 07:30 ET

ImmunityBio Price Target Announced at $8.00/Share by Jefferies

Dow JonesAug 3, 2022 07:26 ET

ImmunityBio Initiated at Buy by Jefferies

Dow JonesAug 3, 2022 07:26 ET

ImmunityBio analyst ratings

Benzinga Analyst RatingsAug 3, 2022 07:18 ET

Jefferies Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $8

Benzinga Real-time NewsAug 3, 2022 07:18 ET

Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating

MT NewswiresMay 31, 2022 05:20 ET